The Role of Hypertonic Saline in the Management of Bronchiolitis at Raparin Hospital

Zina Farhad  Ali; Dler Abdulkhaleq  Nooruldeen

doi:10.56056/

Authors

Zina Farhad Ali M.B.Ch.B, Kurdistan Higher Council of Medical Specialist, Erbil-Kurdistan Region/ Iraq
Dler Abdulkhaleq Nooruldeen M.B.Ch.B, FKHCMS. Pediatric, HD Pediatric Endocrinology, Professor and Consultant Pediatrician, Hawler Medical University, Pediatric Department

DOI:

https://doi.org/10.56056/

Keywords:

Bronchiolitis, Hypertonic saline, Nebulization, Salbutamol

Abstract

Background and objectives: Bronchiolitis is the prevailing acute respiratory ailment of significant severity among newborns and young children. The objective of the study was to assess the effectiveness of hypertonic saline 3% in treating acute bronchiolitis and its impact on the severity of cases admitted to the emergency department, in comparison to Salbutamol nebulization.

Methods: A comparative, experimental, longitudinal study was conducted on 150 infants aged 1–24 months who were admitted to Raparin pediatric teaching hospital at emergency department with moderate to severe respiratory distress from November 2022 to May 2023. Two groups of patients were formed by age and severity. Using a nebulizer device, the two medication combinations (Salbutamol and hypertonic saline) were given to the patients in each of the two groups every six hours. Initial assessment was executed through taking vital signs on admission. Moreover, additional assessments were conducted before and following each nebulization for four times each day until the recovery and discharge. The length of recovery, hospital stay, duration of oxygen therapy, wheezing and oxygen saturation was compared between the two groups.

Results: The study found that 32% of the Salbutamol group stayed 4 days and 18.7% of same group stayed ? 5 days in the hospital respectively, compared with 14.7% of the hypertonic group stayed in hospital for 4 days and 0% stayed ? 5 days in the hospital (p < 0.001). Furthermore, one day after treatment, around half (44%) of children treated with hypertonic saline had no wheeze, compared with 24% of children of the Salbutamol group (p < 0.001).

Conclusion: The present study concluded that the role of Nebulized 3% Hypertonic Saline is significant in management of bronchiolitis.

Downloads

Download data is not yet available.

References

1. Geme JW. Nelson textbook of pediatrics. Elsevier; 2020.

2. Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis. BMJ 2011 Apr 6;342.

3. Chou T, Chen EY, Liu YY, Wu IP, Chien MY, Hsiao HF. A comparison study: Treat acute bronchiolitis infants with hypertonic saline by small volume jet nebulizer and portable vibrating-mesh nebulizer. J Pediatric Infect Dis Soc. 2018; May:3685-A3685.

4. Hsieh CW, Chen C, Su HC, Chen KH. Exploring the efficacy of using hypertonic saline for nebulizing treatment in children with bronchiolitis: a meta-analysis of randomized controlled trials. BMC pediatrics. 2020 Dec;20(1):1-5.

5. Chen YJ, Lee WL, Wang CM, Chou HH. Nebulized hypertonic saline treatment reduces both rate and duration of hospitalization for acute bronchiolitis in infants: an updated meta-analysis. Pediatr Neonatal. 2014 Dec;55(6):431-8.

6. Everard ML, Hind D, Freeman JV, Bradburn M. Late-breaking abstract: Hypertonic saline in acute bronchiolitis: Randomised controlled trial (RCT) and economic evaluation (the SABRE study). Eur. Respir. J. 2014 Sep 1;44(58):345.

7. Brady MT, Byington CL, Davies HD, Edwards KM, Jackson MA, Maldonado YA, et al, Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014 Aug 1;134(2): e620-38.

8. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006 Oct 1;118(4):1774-93.

9. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr. Infect. Dis. 2003 Feb 1;22(2): S76-82.

10. Schauer U, Hoffjan S, Bittscheidt J, Köchling A, Hemmis S, Bongartz S. RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life. Eur. Respir. J. 2002 Nov 1;20(5):1277-83.

11. Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Dixon S. Saline in acute bronchiolitis RCT and economic evaluation: hypertonic saline in acute bronchiolitis-randomised controlled trial and systematic review. Health Technol Assess. 2015 Aug 1;19(66):1-30.

12. Heikkilä P, Renko M, Korppi M. Hypertonic saline inhalations in bronchiolitis—A cumulative meta?analysis. Pediatr Pulmonol. 2018 Feb;53(2):233-42.

13. Zhang L, Mendoza-Sassi RA, Wainwright CE, Aregbesola A, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2023(4).

14. Panitch HB. Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction. J Pediatric Infect Dis Soc. 2003 Feb 1;22(2): S83-8.

15. Pelletier AJ, Mansbach JM, Camargo Jr CA. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics. 2006 Dec 1;118(6):2418-23.

16. Del Giudice MM, Saitta F, Leonardi S, Capasso M, Niglio B, Chinellato I. Effectiveness of nebulized hypertonic saline and epinephrine in hospitalized infants with bronchiolitis. Int J Immunopathol Pharmacol. 2012 Apr;25(2):485-91.

17. Wang ZY,Sun AL,Fu XQ. Efficacy of 3% hypertonic saline in bronchiolitis: A meta-analysis. Exp Ther Med. 2019 Aug 1;18(2):1338-44.

18. Ater D, Shai H, Bar BE, Fireman N, Tasher D, Dalal I. Hypertonic saline and acute wheezing in preschool children. Pediatrics. 2012 Jun 1;129(6): e1397-403.

19. Hsieh CW, Chen C, Su HC, Chen KH. Exploring the efficacy of using hypertonic saline for nebulizing treatment in children with bronchiolitis: a meta-analysis of randomized controlled trials. BMC Pediatr. 2020 Dec; 20:1-5.